KR102805503B1 - Creb 결합 단백질(cbp)의 저해 - Google Patents

Creb 결합 단백질(cbp)의 저해 Download PDF

Info

Publication number
KR102805503B1
KR102805503B1 KR1020217002866A KR20217002866A KR102805503B1 KR 102805503 B1 KR102805503 B1 KR 102805503B1 KR 1020217002866 A KR1020217002866 A KR 1020217002866A KR 20217002866 A KR20217002866 A KR 20217002866A KR 102805503 B1 KR102805503 B1 KR 102805503B1
Authority
KR
South Korea
Prior art keywords
alkyl
methyl
compound
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217002866A
Other languages
English (en)
Korean (ko)
Other versions
KR20210025631A (ko
Inventor
숀 이. 알. 실러
토스텐 허버츠
홍빈 리
브래드포드 그레이브스
스티븐 미쉬키
안젤라 브이. 웨스트
안나 에릭슨
제니퍼 알. 다우닝
Original Assignee
포르마 세라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/051214 external-priority patent/WO2019055869A1/en
Application filed by 포르마 세라퓨틱스 인크. filed Critical 포르마 세라퓨틱스 인크.
Priority to KR1020257014745A priority Critical patent/KR20250067962A/ko
Publication of KR20210025631A publication Critical patent/KR20210025631A/ko
Application granted granted Critical
Publication of KR102805503B1 publication Critical patent/KR102805503B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217002866A 2018-06-29 2019-06-28 Creb 결합 단백질(cbp)의 저해 Active KR102805503B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257014745A KR20250067962A (ko) 2018-06-29 2019-06-28 Creb 결합 단백질(cbp)의 저해

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862692593P 2018-06-29 2018-06-29
US62/692,593 2018-06-29
USPCT/US2018/051214 2018-09-14
PCT/US2018/051214 WO2019055869A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
USPCT/US2018/051235 2018-09-14
PCT/US2018/051235 WO2019055877A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
US201962819490P 2019-03-15 2019-03-15
US62/819,490 2019-03-15
PCT/US2019/039936 WO2020006483A1 (en) 2018-06-29 2019-06-28 Inhibiting creb binding protein (cbp)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257014745A Division KR20250067962A (ko) 2018-06-29 2019-06-28 Creb 결합 단백질(cbp)의 저해

Publications (2)

Publication Number Publication Date
KR20210025631A KR20210025631A (ko) 2021-03-09
KR102805503B1 true KR102805503B1 (ko) 2025-05-09

Family

ID=68987627

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217002866A Active KR102805503B1 (ko) 2018-06-29 2019-06-28 Creb 결합 단백질(cbp)의 저해
KR1020257014745A Pending KR20250067962A (ko) 2018-06-29 2019-06-28 Creb 결합 단백질(cbp)의 저해

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257014745A Pending KR20250067962A (ko) 2018-06-29 2019-06-28 Creb 결합 단백질(cbp)의 저해

Country Status (26)

Country Link
US (3) US10870648B2 (enExample)
EP (1) EP3998266A1 (enExample)
JP (4) JP6781806B2 (enExample)
KR (2) KR102805503B1 (enExample)
CN (2) CN112513038B (enExample)
AU (3) AU2019295790B2 (enExample)
BR (1) BR112020026783A2 (enExample)
CA (1) CA3105099A1 (enExample)
CY (1) CY1124762T1 (enExample)
DK (1) DK3587418T3 (enExample)
ES (1) ES2900105T3 (enExample)
HR (1) HRP20211698T1 (enExample)
HU (1) HUE056885T2 (enExample)
IL (3) IL321337A (enExample)
LT (1) LT3587418T (enExample)
MA (1) MA50675B1 (enExample)
MX (2) MX2023013508A (enExample)
PL (1) PL3587418T3 (enExample)
PT (1) PT3587418T (enExample)
RS (1) RS62732B1 (enExample)
SA (1) SA520420909B1 (enExample)
SG (1) SG11202012767UA (enExample)
SI (1) SI3587418T1 (enExample)
SM (1) SMT202100636T1 (enExample)
WO (1) WO2020006483A1 (enExample)
ZA (1) ZA202100509B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013508A (es) * 2018-06-29 2023-12-13 Forma Therapeutics Inc Inhibicion de la proteina de union a creb (cbp).
CN113784967B (zh) * 2019-03-15 2024-07-26 福马治疗股份有限公司 用于治疗雄激素受体阳性形式的癌症的组合物和方法
TW202102494A (zh) 2019-03-15 2021-01-16 美商弗瑪治療公司 抑制環amp-反應元件-結合蛋白(creb)
KR20230028512A (ko) 2020-06-25 2023-02-28 톨레모 테라퓨틱스 아게 EGFR-돌연변이 NSCLC의 치료에 사용하기 위한 CBP/p300 브로모도메인 억제제 및 EGFR 억제제의 조합물
KR20230028798A (ko) 2020-06-25 2023-03-02 톨레모 테라퓨틱스 아게 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) * 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2019055869A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404207A (en) 1981-11-06 1983-09-13 Riker Laboratories, Inc. Antimicrobial 8-substituted benzo [IJ]quinolizines
US5138089A (en) * 1986-06-27 1992-08-11 The Procter & Gamble Company Chromophores, sunscreen compositions and methods for preventing sunburn
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
US7122227B2 (en) 2000-11-20 2006-10-17 Merck Patent Gesellschaft Chiral photoisomerizable compounds
CA2463136A1 (en) 2001-10-17 2003-04-24 Raymond Andersen Ship 1 modulators
US7622479B2 (en) 2001-11-26 2009-11-24 Takeda Pharmaceutical Company Limited Bicyclic derivative, its production and use
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
IN2003CH00929A (enExample) 2003-11-13 2008-10-06
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
EP1732541A4 (en) 2004-04-07 2008-03-05 Takeda Pharmaceutical CYCLIC COMPOUNDS
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
WO2007120339A1 (en) 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
WO2007133653A2 (en) 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Methods for treating blood disorders
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
CA2574531C (en) 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
US8476458B2 (en) 2007-06-21 2013-07-02 The Wistar Institute Methods and compositions for modulating P300/CBP activity
CN101687815A (zh) 2007-06-26 2010-03-31 塞诺菲-安万特股份有限公司 苯并咪唑和氮杂苯并咪唑的区域选择性铜催化合成
EP2172453A4 (en) 2007-06-27 2010-12-22 Taisho Pharmaceutical Co Ltd CONNECTION WITH 11-β-HSD1 INHIBITING ACTIVITY
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
DK2959900T3 (en) 2008-06-16 2017-06-26 Univ Tennessee Res Found CONNECTION TO TREATMENT OF CANCER
US8604030B2 (en) 2009-03-27 2013-12-10 Kowa Company, Ltd. Fused piperidine compound and pharmaceutical containing same
US20100305093A1 (en) 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
EP2419430A4 (en) 2009-04-15 2012-10-31 Jw Pharmaceutical Corp NEW REVERSE-TURN MIMETIC COMPOSITIONS, METHOD FOR THEIR MANUFACTURE AND USE
CN102459248A (zh) 2009-05-26 2012-05-16 埃克塞里艾克西斯公司 作为PI3K/mTOR抑制剂的苯并氧杂环庚三烯以及它们使用与制造方法
WO2010138490A1 (en) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and methods of their use and manufacture
WO2011085039A2 (en) 2010-01-05 2011-07-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
CN102883607B (zh) 2010-03-01 2015-07-22 Gtx公司 用于治疗癌的化合物
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
CA2827392A1 (en) 2011-02-24 2012-08-30 Emory University Noggin blocking compositions for ossification and methods related thereto
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013148114A1 (en) 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
US9211333B2 (en) 2012-06-05 2015-12-15 Hong Kong Baptist University Anti-cancer agents synthesized based on miliusane compounds
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
CN105407888B (zh) 2013-06-21 2019-05-21 齐尼思表观遗传学有限公司 新双环溴结构域抑制剂
WO2015004534A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
CA2918910A1 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
DE102013215912B3 (de) 2013-08-12 2015-02-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung
UY35834A (es) 2013-11-14 2015-05-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
BR112016011024B1 (pt) 2013-11-18 2020-09-01 Forma Therapeutics, Inc Composto, composição farmacêutica, e, usos dos mesmos
WO2015074081A1 (en) 2013-11-18 2015-05-21 Bair Kenneth W Benzopiperazine compositions as bet bromodomain inhibitors
JP2017529358A (ja) 2014-09-19 2017-10-05 ジェネンテック， インコーポレイテッド がんの処置のためのｃｂｐ／ｅｐ３００阻害剤およびｂｅｔ阻害剤の使用
JP6854776B2 (ja) 2015-01-08 2021-04-07 インぺティス バイオサイエンス リミテッド 二環式化合物、その組成物および医薬用途
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
JP2019516700A (ja) 2016-05-12 2019-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
WO2017205536A2 (en) 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
TWI788343B (zh) * 2017-04-18 2023-01-01 美商塞爾基因定量細胞研究公司 治療用化合物
MX2023013508A (es) * 2018-06-29 2023-12-13 Forma Therapeutics Inc Inhibicion de la proteina de union a creb (cbp).

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2019055869A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300

Also Published As

Publication number Publication date
KR20250067962A (ko) 2025-05-15
US20220162207A1 (en) 2022-05-26
IL279734B2 (en) 2024-11-01
US20200299295A1 (en) 2020-09-24
CA3105099A1 (en) 2020-01-02
MA50675A (fr) 2021-04-07
KR20210025631A (ko) 2021-03-09
SG11202012767UA (en) 2021-01-28
MA50675B1 (fr) 2021-09-30
IL313466A (en) 2024-08-01
JP2025094157A (ja) 2025-06-24
PL3587418T3 (pl) 2022-02-21
IL279734A (en) 2021-03-01
ZA202100509B (en) 2022-12-21
EP3998266A1 (en) 2022-05-18
JP6781806B2 (ja) 2020-11-04
AU2025210762A1 (en) 2025-08-21
LT3587418T (lt) 2021-11-25
AU2019295790B2 (en) 2023-07-13
US10870648B2 (en) 2020-12-22
MX2023013508A (es) 2023-12-13
US11254674B2 (en) 2022-02-22
IL313466B1 (en) 2025-07-01
CN112513038B (zh) 2023-01-10
SA520420909B1 (ar) 2024-11-12
PT3587418T (pt) 2021-12-02
JP2020002135A (ja) 2020-01-09
JP7017801B2 (ja) 2022-02-09
IL279734B1 (en) 2024-07-01
WO2020006483A1 (en) 2020-01-02
AU2019295790A1 (en) 2021-01-28
AU2023226653A1 (en) 2023-09-21
HRP20211698T1 (hr) 2022-02-18
CN112513038A (zh) 2021-03-16
US12378242B2 (en) 2025-08-05
US20200002332A1 (en) 2020-01-02
RS62732B1 (sr) 2022-01-31
CN116178369A (zh) 2023-05-30
SI3587418T1 (sl) 2022-03-31
IL313466B2 (en) 2025-11-01
IL321337A (en) 2025-08-01
JP2021042255A (ja) 2021-03-18
AU2023226653B2 (en) 2025-09-04
CY1124762T1 (el) 2022-07-22
HUE056885T2 (hu) 2022-03-28
ES2900105T3 (es) 2022-03-15
DK3587418T3 (da) 2021-10-11
BR112020026783A2 (pt) 2021-03-30
JP2020128426A (ja) 2020-08-27
MX2020014303A (es) 2021-03-25
SMT202100636T1 (it) 2022-01-10

Similar Documents

Publication Publication Date Title
KR102805503B1 (ko) Creb 결합 단백질(cbp)의 저해
TWI795440B (zh) 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物
WO2018024188A1 (zh) 多环化合物、其制备方法、药物组合物及应用
US20250304583A1 (en) Inhibiting g cyclic amp-responsive element-binding protein (creb) binding protein (cbp)
CN112823037A (zh) 抑制去泛素化酶usp25和usp28
EP3587418B1 (en) Inhibitors of creb binding protein (cbp)
HK40074924A (en) Inhibiting creb binding protein (cbp)
RU2803290C2 (ru) Ингибирование creb-связывающего белка (cbp)
HK40018316A (en) Inhibitors of creb binding protein (cbp)
HK40018316B (en) Inhibitors of creb binding protein (cbp)
CN113874017A (zh) 抑制环amp-应答元件结合蛋白(creb)
MD3587418T2 (ro) Inhibitori ai proteinei de legare CREB (CBP)
WO2020190791A1 (en) Inhibiting cyclic amp-responsive element-binding protein (creb)
EA046876B1 (ru) Ингибирование creb-связывающего белка (cbp)
BR122025003836A2 (pt) Composto e composição farmacêutica
EA042920B1 (ru) Ингибирование creb-связывающего белка (cbp)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210127

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220627

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240610

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250205

PG1601 Publication of registration